Protherics Plc - Report of Foreign Issuer (6-K)
December 27 2007 - 6:22AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
21 December 2007
PROTHERICS PLC
(Translation of Registrant’s Name Into
English)
The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form
40-F
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):
Indicate by check mark whether the registrant by
furnishing the information contained in this form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
of 1934.
Yes
No
X
If “Yes” is marked, indicate below the
file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
.
The Registrant is furnishing a copy of its
announcements as reported to the Company Announcements Office of the London Stock
Exchange.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PROTHERICS PLC
|
|
|
|
|
|
|
|
|
|
Date: (Date)
|
|
By:
|
|
/s/ Rolf Soderstrom
|
|
|
|
|
|
Rolf Soderstrom
|
|
|
|
|
|
Finance Director
|
Protherics PLC
Notification of Major Interests in Shares
London, UK; Brentwood, TN, US: 21 December 2007 -
Protherics PLC
(“Protherics” or the “Company”), the international
biopharmaceutical company focused on critical care and cancer, announces that on 20
December 2007, in accordance with the Transparency Obligations Directive, a notification of
interest in the ordinary share capital of the Company was received from AXA Investment
Managers UK Limited on behalf of AXA S.A. and its Group Companies (“AXA”). The
notification follows an increase in the Indirect holding of AXA. Details of the interest
notified are as follows:
|
1. Reason for the notification
(please tick the appropriate box or
boxes)
|
|
|
An acquisition of voting rights
|
X
|
|
An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached
|
|
|
An event changing the breakdown of voting rights
|
|
|
Other (please specify):
|
|
|
2. Full name of person(s) subject to the notification obligation:
|
AXA S.A., 25 Avenue Matignon, 75008 Paris and its group of companies.
|
|
3. Full name of shareholder(s) (if different from 2.):
|
|
|
4. Date of the transaction (and date on which the threshold is crossed or
reached if different):
|
18 December 2007
|
|
5. Date on which issuer notified:
|
19 December 2007
|
|
6. Threshold(s) that is/are crossed or reached:
|
14%
|
|
7. Notified details:
|
|
|
|
|
|
A: Voting rights attached to shares
|
|
Class/type of shares
if possible using the ISIN CODE
|
Situation previous to the Triggering
transaction
|
Resulting situation after the triggering
transaction
|
|
Number of Shares
|
Number of Voting Rights
|
Number of shares
|
Number of voting rights
|
% of voting rights
|
|
|
Direct
|
Direct
|
Indirect
|
Direct
|
Indirect
|
|
0702920
|
43,726,012
|
43,726,012
|
741,666
|
741,666
|
48,854,003
|
0.22%
|
14.36%
|
|
B: Financial Instruments
|
|
Resulting situation after the triggering
transaction
|
|
Type of financial instrument
|
Expiration date
|
Exercise/ Conversion Period/
Date
|
Number of voting rights that may be acquired
if the instrument is exercised/ converted.
|
% of voting rights
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total (A+B)
|
|
Number of voting rights
|
% of voting rights
|
|
49,595,669
|
14.58%
|
|
8. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable :
|
|
Name of Company/Fund
|
Number of Shares
|
% of issued share capital
|
|
AXA UK Investment Co ICVC
UK Smaller Companies Fund
Indirect
|
551,929
|
|
0.16224
|
|
|
Sun Life Pensions Management Ltd
Direct
|
25,000
|
|
0.00735
|
|
|
Sun Life Unit Assurance Ltd
FTSE All Share Tracker
Direct
|
53,913
|
|
0.01585
|
|
|
Sun Life Pensions Management
FTSE All Share Tracker
Direct
|
294,874
|
|
0.08668
|
|
|
AXA Framlington
SEI UK Equity
Indirect
|
750,000
|
|
0.22046
|
|
|
AXA Framlington
St James Place Exempt (Pens) Fund
Indirect
|
1,600,000
|
|
0.47031
|
|
|
AXA Framlington
St James Place Net (Life) Fund
Indirect
|
1,800,000
|
|
0.52910
|
|
|
AXA Framlington
St James Place Offshore Fund
Indirect
|
400,000
|
|
0.11758
|
|
|
AXA Framlington
Daimler Chrysler
Indirect
|
600,000
|
|
0.17637
|
|
|
AXA Framlington
Throgmorton Trust
Indirect
|
3,120,333
|
|
0.91720
|
|
|
AXA Framlington
UK Select Ops
Indirect
|
15,013,453
|
|
4.41308
|
|
|
AXA Framlington
Equity Income
Indirect
|
13,753,131
|
|
4.04262
|
|
|
AXA Framlington
Managed Balanced
Indirect
|
2,000,000
|
|
0.58788
|
|
|
AXA Framlington
UK Smaller Companies
Indirect
|
1,500,000
|
|
0.44091
|
|
|
AXA Framlington
BAE Systems Pensions Fund CIF Trustees
Indirect
|
500,000
|
|
0.14697
|
|
|
AXA Framlington
BAE Systems 2000 Pensions Fund
Indirect
|
220,000
|
|
0.06467
|
|
|
Framlington onshore private clients
Indirect
|
6,820,157
|
|
2.00473
|
|
|
Axa Sun Life With Profits Passive
Direct
|
226,817
|
|
0.06667
|
|
|
Sun Life Ass With Profits Passive
Direct
|
141,062
|
|
0.04146
|
|
|
AXA Framlington
St James Place Internal Equity & Income
UT
Indirect
|
225,000
|
|
0.06614
|
|
|
Total Direct
Total Indirect
|
741,666
48,854,003
|
|
0.21801
14.36024
|
|
|
TOTAL
|
49,595,669
|
|
14.57825
|
|
|
|
|
Proxy Voting:
|
|
9. Name of the proxy holder:
|
|
|
10. Number of voting rights proxy holder will cease to hold:
|
|
|
11. Date on which proxy holder will cease to hold voting rights:
|
|
|
|
|
|
|
|
|
|
12. Additional information:
|
|
| Ends |
For further information please contact:
|
Protherics
|
|
|
Nick Staples,
Director of Corporate
Affairs
|
+44 (0) 7919 480510
|
|
Julie Vickers, Company Secretary
|
+44 (0)1928 518010
|
|
|
|
|
Financial Dynamics
– press
enquiries
|
|
|
London: Ben Atwell,
Lara Mott
|
+44 (0) 20 7831 3113
|
|
New York: John Capodanno, Jonathan Birt
|
+1 212 850 5600
|
Or visit
www.protherics.com
END
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From May 2024 to Jun 2024
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Jun 2023 to Jun 2024
